Do investors value the FDA orphan drug designation?

Схожие документы

• Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
  по: Miller, Kathleen L., et al.
  Опубликовано: (2021)
• FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis
  по: Garbade, Sven F., et al.
  Опубликовано: (2020)
• The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database
  по: Johann, Pascal, et al.
  Опубликовано: (2021)
• Precision Medicines’ Impact on Orphan Drug Designation
  по: Mueller, Christine M., et al.
  Опубликовано: (2019)
• The Push for Additional Orphan Drugs: Can the FDA Do More to Encourage Their Development?
  по: Barlas, Stephen
  Опубликовано: (2016)